Xenon Pharmaceuticals (XENE) Current Assets (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Current Assets data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Current Assets rose 95.68% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 95.68% increase from a year earlier, with the FY2025 full-year figure at $560.6 million, down 11.75% from the prior year.
• Current Assets for Q1 2026 stood at $1.1 billion, up from $560.6 million in the prior quarter.
• Over the last five years, Current Assets for XENE reached as high as $1.1 billion in Q1 2026 and fell as low as $480.1 million in Q3 2025.
• Historically, Current Assets has averaged $634.5 million across 5 years, with a median of $600.3 million in 2022.
• Across the five-year window, Current Assets surged 197.95% in 2022 and plunged 31.48% in 2023, its largest moves.
• Year by year, Current Assets stood at $600.3 million in 2022, then grew by 7.44% to $645.0 million in 2023, then fell by 1.5% to $635.3 million in 2024, then retreated by 11.75% to $560.6 million in 2025, then soared by 97.38% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.1 billion in Q1 2026, $560.6 million in Q4 2025, and $480.1 million in Q3 2025.